Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Population consisted of all participants in the Safety analysis set for whom at least one evaluable pharmacokinetic sample was obtained and analyzed.

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Population consisted of all participants in the Safety analysis set for whom at least one evaluable pharmacokinetic sample was obtained and analyzed. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Population consisted of all participants in the Safety analysis set for whom at least one evaluable pharmacokinetic sample was obtained and analyzed.

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Population consisted of all participants in the Safety analysis set for whom at least one evaluable pharmacokinetic sample was obtained and analyzed.

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Population consisted of all participants in the Safety analysis set for whom at least one evaluable pharmacokinetic sample was obtained and analyzed. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Population consisted of all participants in the Safety analysis set for whom at least one evaluable pharmacokinetic sample was obtained and analyzed. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Population consisted of all participants in the Safety analysis set for whom at least one evaluable pharmacokinetic sample was obtained and analyzed. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Population consisted of all participants in the Safety analysis set for whom at least one evaluable pharmacokinetic sample was obtained and analyzed. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Population consisted of all participants in the Safety analysis set for whom at least one evaluable pharmacokinetic sample was obtained and analyzed.

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods. The percentage of AUC (0-inf) obtained by extrapolation (%AUCex) was calculated as: (AUC[0-inf] - AUC[0-t]) /AUC(0-inf)*100.

Pharmacokinetic Population consisted of all participants in the Safety analysis set for whom at least one evaluable pharmacokinetic sample was obtained and analyzed. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the 'Overall Number of Participants Analyzed' field.

Blood samples were collected and analyzed for the presence of anti- depemokimab antibodies using a validated immunoassay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Safety Population included all participants who received at least 1 dose of study intervention. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for specified time points.

Blood samples were collected for determination of positive neutralizing antibodies. A neutralizing antibody assay was performed. Neutralizing antibody test was only carried out for participants who have had a positive confirmatory binding antibody test result at visit. A participant was considered positive if they had at least one positive post-Baseline neutralizing antibody result. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Safety Population included all participants who received at least 1 dose of study intervention. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for specified time points.